Reduction in oxaliplatin-related neurotoxicity by the administration of Keishikajutsubuto (TJ-18) and powdered processed aconite root

Japanese Journal of Cancer and Chemotherapy

Volumn 39, Issue 11, 2012, Pages 1687-1691

  Yamada, Takeshi ^a   Kan, Hayato ^a   Matsumoto, Satoshi ^a   Koizumi, Michihiro ^a   Sasaki, Junpei ^a   Tani, Aya ^a   Yokoi, Kimiyoshi ^a   Uchida, Eiji ^a  

^a NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

Author keywords

FOLFOX; Keishikajutsubutou; Peripheral neuropathy; Powdered processed aconite root

Indexed keywords

FLUOROURACIL; FOLINIC ACID; NEUROPROTECTIVE AGENT; OXALIPLATIN; T 3023; TJ 18; UNCLASSIFIED DRUG;

ACONITE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CANCER; DRUG RESPONSE; HUMAN; MULTIPLE CYCLE TREATMENT; NEUROPATHY;

EID: 84872709692     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Cascinu S, Catalano V, Cordella L, et al: Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20(16): 3478-3483, 2002.
2. Wilson RH, Lehky T, Thomas RR, et al: Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20(7) : 1767-1774, 2002.
3. Grothey A, Nikcevich DA, Sloan JA, et al: Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 29(4): 421-427, 2011.
4. Tournigand C, Cervantes A, Figer A, et al: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer - a GERCOR study. J Clin Oncol 24(3): 394-400, 2006.
5. Boku N, Ohtsu A, Hyodo I, et al: Phase II study of oxaliplatin in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines. Jpn J Clin Oncol 37(6): 440-445, 2007.
6. André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19): 3109-3116, 2009.
7. Nassini R, Gees M, Harrison S, et al. Oxaliplatin elicits mechanical and cold allodynia in rodents via TRPA1 receptor stimulation. Pain 152(7): 1621-1631, 2011.
8. Zhang Y, Sreekrishna K, Lin Y, et al: Modulation of transient receptor potential (TRP) channels by Chinese herbal extracts. Phytother Res 25(11): 1666-1670, 2011.
9. Nishioka M, Shimada M, Kurita N, et al: The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol 16(4): 322-327, 2011.
10. Gauchan P, Andoh T, Kato A, et al: Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. Neurosci Lett 458(2): 93-95, 2009.